youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
DGX:NYSE
Quest Diagnostics Inc
$234.91
arrow_downward
-0.02%(-0.050) 1D
$234.91
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 19, 4:00:08 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DGX...
Open
$234.40
High
$235.99
Low
$233.82
Mkt. cap
25.93B
Avg. vol.
1.10M
Volume
864.18K
Dividend
1.46%
Quarterly dividend
$0.86
Ex-dividend date
Oct 6, 2026
P/E ratio
24.97
52-wk high
$248.84
52-wk low
$171.18
EPS
$9.41
Beta
0.54
Shares outstanding
110.37M
No. of employees
52K
Open
$234.40
High
$235.99
Low
$233.82
Mkt. cap
25.93B
Avg. vol.
1.10M
Volume
864.18K
Dividend
1.46%
Quarterly dividend
$0.86
Ex-dividend date
Oct 6, 2026
P/E ratio
24.97
52-wk high
$248.84
52-wk low
$171.18
EPS
$9.41
Beta
0.54
Shares outstanding
110.37M
No. of employees
52K
News stories
From web sources and news partners
Simply Wall Street
·
11 hours ago
Quest Diagnostics (DGX) Stock Could Be Cheap Despite A 105% Run
Profile
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing. Wikipedia
About Quest Diagnostics Inc
CEOJames E. Davis
Employees51.5K
Founded1967
Headquarters-
SectorHealth care provider
Websitequestdiagnostics.com
Analyst ratings
Based on 11 analysts giving stock ratings to DGX in the past 3 months
Buy
Buy
7
Hold
4
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for DGX in the last 3 months.
Highest
Current $234.91
$265.00 (+12.81%)
Average
$256.50 (+9.19%)
Lowest
$245.00 (+4.30%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Kevin Caliendo UBS | Hold | Reiterated | $250.00 | +6.4% | 10/19/2026 |
Luke Sergott Barclays | Buy | Maintained | $260.00 | +10.7% | 10/07/2026 |
David S Macdonald Truist Financial | Hold | Reiterated | $260.00 | +10.7% | 09/22/2026 |
Erin Wright Morgan Stanley | Buy | Maintained | $260.00 | +10.7% | 08/19/2026 |
David Toung Argus Research | Buy | Maintained | $260.00 | +10.7% | 07/28/2026 |
Ann Hynes Mizuho Securities | Buy | Maintained | $260.00 | +10.7% | 07/28/2026 |
Lisa Gill J.P. Morgan | Hold | Reiterated | $250.00 | +6.4% | 07/28/2026 |
Michael Ryskin Bank of America Securities | Buy | Reiterated | $265.00 | +12.8% | 07/24/2026 |
Eric Coldwell Robert W. Baird | Hold | Maintained | $255.00 | +8.6% | 07/24/2026 |
Tycho Peterson Jefferies | Buy | Reiterated | $245.00 | +4.3% | 07/23/2026 |
Jared Haase William Blair | Buy | Maintained | - | - | 07/23/2026 |
Andrew Brackmann William Blair | Buy | Maintained | - | - | 06/15/2026 |
Elizabeth Anderson CFA Evercore ISI | Hold | Maintained | $210.00 | -10.6% | 04/20/2026 |
Patrick B Donnelly Citi | Hold | Maintained | $215.00 | -8.5% | 02/11/2026 |
Next call in 3 days
Thu, Oct 22, 2:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.87
Revenue / Est. (USD)
- / 3.05B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 2.82B | 2.81B | 2.90B | 3.04B |
Cost of goods sold | 1.86B | 1.89B | 1.95B | 2.02B |
Cost of revenue | 1.86B | 1.89B | 1.95B | 2.02B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 491.00M | 486.00M | 498.00M | 526.00M |
Operating expense | 531.00M | 523.00M | 533.00M | 564.00M |
Total operating expenses | 2.40B | 2.41B | 2.48B | 2.58B |
Operating income | 420.00M | 392.00M | 411.00M | 464.00M |
Other non operating income | 8.00M | 9.00M | -2.00M | 16.00M |
EBT including unusual items | 336.00M | 337.00M | 338.00M | 422.00M |
EBT excluding unusual items | 370.00M | 344.00M | 350.00M | 427.00M |
Income tax expense | 77.00M | 81.00M | 74.00M | 88.00M |
Effective tax rate | 22.92% | 24.04% | 21.89% | 20.85% |
Other operating expenses | 1.00M | - | -2.00M | - |
Net income | 245.00M | 245.00M | 252.00M | 320.00M |
Net profit margin | 8.70% | 8.73% | 8.70% | 10.52% |
Earnings per share | 2.60 | 2.42 | 2.50 | 3.12 |
Interest and investment income | 3.00M | 3.00M | 2.00M | 5.00M |
Interest expense | -69.00M | -67.00M | -65.00M | -68.00M |
Net interest expenses | -66.00M | -64.00M | -63.00M | -63.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 562.00M | 537.00M | 558.00M | 610.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1